KR20250010025A - 도입유전자 발현 및 핵 국소화를 개선하기 위한 트랜스포사제의 용도 - Google Patents

도입유전자 발현 및 핵 국소화를 개선하기 위한 트랜스포사제의 용도 Download PDF

Info

Publication number
KR20250010025A
KR20250010025A KR1020247040630A KR20247040630A KR20250010025A KR 20250010025 A KR20250010025 A KR 20250010025A KR 1020247040630 A KR1020247040630 A KR 1020247040630A KR 20247040630 A KR20247040630 A KR 20247040630A KR 20250010025 A KR20250010025 A KR 20250010025A
Authority
KR
South Korea
Prior art keywords
transposase
protein
nucleic acid
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
KR1020247040630A
Other languages
English (en)
Korean (ko)
Inventor
가르시아 아벤치아 산체스-메히아스
카르골 마르크 구엘
마스미차 마리아 팔라레스
Original Assignee
인테그라 테라퓨틱스
우니베르시타트 폼페우 파브라
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 인테그라 테라퓨틱스, 우니베르시타트 폼페우 파브라 filed Critical 인테그라 테라퓨틱스
Publication of KR20250010025A publication Critical patent/KR20250010025A/ko
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C12N9/222—Clustered regularly interspaced short palindromic repeats [CRISPR]-associated [CAS] enzymes
    • C12N9/226—Class 2 CAS enzyme complex, e.g. single CAS protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases [RNase]; Deoxyribonucleases [DNase]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/09—Fusion polypeptide containing a localisation/targetting motif containing a nuclear localisation signal
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2800/00—Nucleic acids vectors
    • C12N2800/90—Vectors containing a transposable element

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Plant Pathology (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020247040630A 2022-05-13 2023-05-12 도입유전자 발현 및 핵 국소화를 개선하기 위한 트랜스포사제의 용도 Pending KR20250010025A (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US202263341619P 2022-05-13 2022-05-13
US63/341,619 2022-05-13
EP22191966 2022-08-24
EP22191966.5 2022-08-24
PCT/EP2023/062736 WO2023218021A1 (en) 2022-05-13 2023-05-12 Use of transposases for improving transgene expression and nuclear localization

Publications (1)

Publication Number Publication Date
KR20250010025A true KR20250010025A (ko) 2025-01-20

Family

ID=86605260

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020247040630A Pending KR20250010025A (ko) 2022-05-13 2023-05-12 도입유전자 발현 및 핵 국소화를 개선하기 위한 트랜스포사제의 용도

Country Status (7)

Country Link
EP (1) EP4522735A1 (https=)
JP (1) JP2025518638A (https=)
KR (1) KR20250010025A (https=)
CN (1) CN119487184A (https=)
AU (1) AU2023269540A1 (https=)
CA (1) CA3253152A1 (https=)
WO (1) WO2023218021A1 (https=)

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110047635A1 (en) * 2006-08-28 2011-02-24 University of Hawail Methods and compositions for transposon-mediated transgenesis
CA3082450A1 (en) * 2017-11-21 2019-05-31 Crispr Therapeutics Ag Materials and methods for treatment of autosomal dominant retinitis pigmentosa
US12338453B2 (en) * 2018-12-17 2025-06-24 Consejo Superior De Investigaciones Científicas (Csic) Method for the introduction of genetic information in cell by site-specific integration system
WO2020243085A1 (en) 2019-05-24 2020-12-03 The Trustees Of Columbia University In The City Of New York Engineered cas-transposon system for programmable and site-directed dna transpositions
CN115968301A (zh) * 2020-04-20 2023-04-14 综合Dna技术公司 优化的蛋白融合和接头
MX2022015284A (es) * 2020-06-05 2023-01-19 Univ California Composiciones y metodos para la edicion del epigenoma.
CA3173696A1 (en) * 2020-07-17 2022-01-20 Volker Sandig Hyperactive transposons and transposases
AU2021403660A1 (en) 2020-12-16 2023-07-06 Universitat Pompeu Fabra Programmable transposases and uses thereof

Also Published As

Publication number Publication date
JP2025518638A (ja) 2025-06-18
CA3253152A1 (en) 2023-11-16
CN119487184A (zh) 2025-02-18
EP4522735A1 (en) 2025-03-19
AU2023269540A1 (en) 2024-11-07
WO2023218021A1 (en) 2023-11-16

Similar Documents

Publication Publication Date Title
CN110891420B (zh) Cas转基因小鼠胚胎干细胞和小鼠及其应用
US11021719B2 (en) Methods and compositions for assessing CRISPER/Cas-mediated disruption or excision and CRISPR/Cas-induced recombination with an exogenous donor nucleic acid in vivo
AU2020379046B2 (en) CRISPR and AAV strategies for X-linked juvenile retinoschisis therapy
US12317874B2 (en) Method of using a genetically modified mouse that expresses human albumin
TW202444910A (zh) 編碼casx之信使rna
KR20240037299A (ko) Crispr/cas 편집 시스템용 가이드 rna
US20190032156A1 (en) Methods and compositions for assessing crispr/cas-induced recombination with an exogenous donor nucleic acid in vivo
CN118632622A (zh) 突变型肌纤蛋白疾病模型及其用途
US20230081547A1 (en) Non-human animals comprising a humanized klkb1 locus and methods of use
KR20250010025A (ko) 도입유전자 발현 및 핵 국소화를 개선하기 위한 트랜스포사제의 용도
US20250269057A1 (en) Therapeutic lama2 payload for treatment of congenital muscular dystrophy
US20220411826A1 (en) Co-opting regulatory bypass repair of genetic diseases
RU2833486C1 (ru) Стратегии crispr и aav для терапии х-сцепленного ювенильного ретиношизиса
WO2026059836A1 (en) Lipid nanoparticles and methods of use

Legal Events

Date Code Title Description
PA0105 International application

St.27 status event code: A-0-1-A10-A15-nap-PA0105

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

P11 Amendment of application requested

Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE)

P11-X000 Amendment of application requested

St.27 status event code: A-2-2-P10-P11-nap-X000